Evidence map›Paper›PMID 36698421›Full record

ArticleFrontiers in oncology2022

Incidence of second primary malignancies in women with different stages of breast cancer.

Cheng-Yao Lin, Sheng-Yen Hsiao, Wen-Tsung Huang, Chao-Jung Tsao, Chung-Han Ho, Shih-Bin Su, How-Ran Guo

Open access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Cheng-Yao LinDivision of Hematology-Oncology, Department of Internal Medicine, Chi Mei Medical Center, Tainan, Taiwan.
Sheng-Yen HsiaoDivision of Hematology-Oncology, Department of Internal Medicine, Chi Mei Medical Center, Tainan, Taiwan.
Wen-Tsung HuangDivision of Hematology-Oncology, Department of Internal Medicine, Chi Mei Medical Center, Tainan, Taiwan.
Chao-Jung TsaoDivision of Hematology-Oncology, Department of Internal Medicine, Chi Mei Medical Center, Tainan, Taiwan.
Chung-Han HoDepartment of Medical Research, Chi Mei Medical Center, Tainan, Taiwan.
Shih-Bin SuDepartment of Medical Research, Chi Mei Medical Center, Liouying, Tainan, Taiwan.
How-Ran GuoDepartment of Environmental and Occupational Health, National Cheng Kung University, Tainan, Taiwan.
Chi Mei Medical Center · TWChia Nan University of Pharmacy and Science · TWNational Cheng Kung University · TWSouthern Taiwan University of Science and Technology · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Breast cancer (BC) is the most common cancer in women worldwide. Because of the extended survival of patients with BC, the occurrence of second primary malignancies (SPMs) after BC is an important issue. Methods: We identified female patients with BC in the Breast Cancer Health Database of Taiwan, which includes four cancer registry datasets between 2002 and 2014 from Taiwan Cancer Registry. We compared the incidence of SPM between patients who received chemotherapy and/or radiotherapy with those who did not. Stratified analyses were performed according to the American Joint Committee on Cancer (AJCC) stage. The Cox regression model was used to identify the risk factors for SPM and evaluate their effects. Results: We enrolled 85,947 eligible patients with BC, and 2,656 (3.09%) patients developed SPM. The median duration of SPM was 2.70 (1.14-5.14) years. Radiotherapy was administered in 40,946 (47.64%) patients, and chemotherapy was administered in 52,120 (60.64%). The most common SPMs were digestive tract cancers (876, 31.89%). The risk factors for SPM included the AJCC stage, chemotherapy, radiotherapy, age, and underlying comorbidities. Neither chemotherapy nor radiotherapy was associated with an increased risk of SPM in any stage. In contrast, after adjusting for other risk factors, patients at stage III/IV who received both therapies had lower risks of SPM compared with those who did not ( Conclusion: The risk of SPM was different across BC stages. Neither chemotherapy nor radiotherapy was associated with an increased risk of SPM in women with BC.

Indexed as

breast cancercancer stagechemotherapyradiotherapysecond primary malignancies

Identifiers

PMID36698421
PMCPMC9868938
OpenAlexW4315480375

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.